Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASTRO 2022 | The potential of using a genome-based model for adjusting radiotherapy dose in multiple cancers

Jacob Scott • 27 Oct 2022
ASTRO 2022
General

Jacob Scott, MD, DPhil, Cleveland Clinic, Cleveland, OH, discusses a genome adjusted radiation dose (GARD), a novel algorithm to personalize prescription of radiation dose, which outperform a nongenomic-based dosing strategy in multiple cancers. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jacob Scott

4:02
The predictive & prognostic value of genomic adjusted radiation dose (GARD) for oropharyngeal cancer
Jacob Scott • 27 Oct 2022
2:11
A genome-based model for adjusting radiotherapy dose
Jacob Scott • 27 Oct 2022

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals